SOUTH SAN FRANCISCO, Calif.,
Nov. 1, 2021 /PRNewswire/
-- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic
lethality focused precision medicine oncology company committed to
the discovery and development of targeted therapeutics, announced
its participation in investor conferences in November 2021.
Northland Capital Biotech Best Ideas Event
Wednesday, November 17, 2021
- CEO Roundtable with IDEAYA participation by Yujiro Hata, Chief Executive Officer, hosted by
Tim Chiang, Managing Director,
Senior Analyst at 9:30am ET
- Panel Discussion "New Advances in Synthetic Lethality", with
IDEAYA participation by Michael White Ph.D., Chief Scientific
Officer, participating at 10:45am
ET
- Company Presentation by Yujiro
Hata, Chief Executive Officer, at 1:00pm ET
Jefferies London Healthcare Conference
Thursday, November 18, 2021
- Fireside chat with Yujiro Hata,
Chief Executive Officer, hosted by Maury Raycroft Ph.D., Equity
Research Analyst, at 6:00pm GMT
A live audio webcast of each event will be available, as
permitted by conference host, at the "Investors/News and
Events/Investor Calendar" section of the IDEAYA website at
https://ir.ideayabio.com/events. A replay of available
webcasts will be accessible for 30 days following the live
event.
About IDEAYA Biosciences
IDEAYA is a synthetic lethality-focused precision medicine
oncology company committed to the discovery and development of
targeted therapeutics for patient populations selected using
molecular diagnostics. IDEAYA's approach integrates
capabilities in identifying and validating translational biomarkers
with drug discovery to select patient populations most likely to
benefit from its targeted therapies. IDEAYA is applying its
early research and drug discovery capabilities to synthetic
lethality – which represents an emerging class of precision
medicine targets.
Forward-Looking Statements
This press release contains forward-looking statements,
including, but not limited to, statements related to participation
in and/or presentation at certain investor relations events. IDEAYA
undertakes no obligation to update or revise any forward-looking
statements. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to the business of IDEAYA in general, see IDEAYA's
Quarterly Report on Form 10-Q filed on August 10, 2021 and any current and periodic
reports filed with the U.S. Securities and Exchange Commission.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-to-participate-in-investor-conferences-in-november-2021-301412397.html
SOURCE IDEAYA Biosciences, Inc.